Searched for
PFIZER CANDIDATE
Johnson & Johnson prostate cancer drug reduces risk of cancer spread and death in late-stage studyThe study, which followed patients for over five years, found that those who received the regimen were nine times more likely to have lit...
Pfizer signs licensing deal worth about $6 billion with China's 3SBio for cancer drugPfizer and 3SBio Inc. have entered into a licensing agreement valued at approximately $6 billion for the development, manufacturing, and co...
Pfizer to buy 8.1% stake in French vaccines company ValnevaValneva will use the proceeds from Pfizer's equity investment to support its Phase 3 development contribution to the Lyme disease program. ...
Pfizer, BioNTech begin vaccine trial to target new strainThe study will have 1,420 subjects, with three cohorts examining different regimens of the current Pfizer-BioNTech Covid vaccine or an Omic...
Pfizer-BioNTech begin trials of new vaccine against Omicron variantThe study will have 1420 subjects, with three cohorts examining different regimens of the current Pfizer-BioNTech COVID vaccine or an Omicr...
Pfizer begins testing use of pnuemococcal vaccine along with COVID-19 booster shotThe study will include 600 adults over 65 years who will be recruited from the late-stage study of the Pfizer-BioNTech COVID-19 vaccine, an...
Pfizer begins early-stage study of oral drug to combat coronavirusThe drugmaker, which developed the first authorized COVID-19 vaccine in the U.S. with Germany's BioNTech SA, said the antiviral candidate s...
Explained: Where does the world stand in the race for a coronavirus vaccine?The following is what we know about the race to deliver vaccines to help end the coronavirus pandemic, which has killed more than 1.8 milli...
Novavax''s COVID vaccine to be studied in the USThe candidate made by Novavax Inc. is the fifth to reach final-stage testing in the U.S. Some 30,000 volunteers are needed to prove if this...
Committed to engaging with Indian govt to make vaccine available in country: PfizerThe UK on Wednesday became the first country to approve the Pfizer/BioNTech vaccine against COVID-19 with the UK regulator Medicines and He...
EU regulator could approve Covid vaccines 'late 2020, early 2021'The Amsterdam-based EMA is carrying out "rolling reviews" designed to speed up vaccine approval times on three candidates: Pfizer-BioNTech,...
Pfizer shares surge nearly 4% on vaccine reportGlobal drugmakers Pfizer and BioNTech said on Wednesday that their COVID-19 vaccine was found 95 per cent effective in the final analysis o...
Protein-based COVID-19 vaccine candidates would be more suitable for India, scientists sayThe decision on procuring the right COVID-19 vaccine depends on multiple factors, including safety, price and ease of deployment, the scien...
Govt pins hopes on 5 Covid shots under trial in IndiaNiti Aayog member Dr V K Paul, who also heads the national expert group on vaccine administration, said all these vaccines were on easy pla...
India health authorities betting on AstraZeneca, Bharat Biotech vaccines“India will have to focus on the indigenous vaccines and the AstraZeneca-Oxford vaccine. These vaccines are being tested in the India popul...
Croda strikes deal with Pfizer to supply COVID-19 vaccine additivesThe contract with Pfizer runs for five years and awards Croda an initial supply contract for four component excipients used in the producti...
UK says expects to receive 10 million doses of Pfizer/BioNTech vaccine this yearThe spokesman said that Britain had now ordered 40 million doses of the candidate vaccine developed by Pfizer and BioNTech, one of six that...
Pfizer not yet ready to release COVID-19 vaccine data from late-stage trialPharma major Pfizer Inc said the company could release data on whether or not the vaccine works as early as this month.
U.S. to pay Pfizer and BioNTech $1.95 billion to produce millions of doses of COVID-19 vaccinePfizer will deliver the doses if the product receives Emergency Use Authorization or licensure from the U.S. Food and Drug Administration, ...
- Pfizer halts cholesterol drug trial, shares may take a hit
Pfizer’s shares will likely plunge after the world’s biggest drugmaker unexpectedly ended development of its most important new drug, a cho...